Monitoring and reporting adverse events

The safety of child participants is the paramount obligation of everyone involved in a clinical trial. Robust systems for identifying, documenting, assessing and reporting adverse events are core requirements of good clinical practice and must be established before a trial begins. In paediatric trials, these systems require additional consideration beyond standard adult frameworks, because children may experience adverse reactions that differ from adults in their nature, frequency, severity and clinical presentation and because the potential for effects on growth, development and long-term organ function introduces safety concerns that may not become apparent until years or decades after exposure

Definitions and terms

A consistent understanding of terminology is essential for accurate and comparable safety data across sites. The following definitions, drawn from ICH E2A (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting), apply in all paediatric clinical trials.

  • Adverse event – any untoward health occurrence in a participant administered a pharmaceutical product, whether or not it is considered causally related to the treatment. Includes any unfavourable and unintended sign, symptom or disease temporally associated with the use of a medicinal product.
  • Serious adverse event – any adverse event that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, results in a congenital anomaly or birth defect or is considered medically significant by the investigator even if it does not meet the above criteria.
  • Suspected unexpected serious adverse reaction is a serious adverse event that is both causally suspected to be related to the investigational product and is not consistent with the information in the investigator’s brochure or product information. Suspected unexpected serious adverse reactions trigger expedited reporting obligations to regulatory authorities and ethics committees.

Why adverse event monitoring requires particular attention for children

Children may be unable to recognize, articulate or report symptoms accurately, especially younger children and those with developmental difficulties. This means that adverse events may go undetected or be underreported unless active surveillance strategies are used, for example, structured symptom checklists, caregiver-reported outcome measures and regular clinical assessments. Observer-reported outcomes, in which caregivers report on behalf of the child, are standard for younger age groups, whereas age-appropriate child self-report measures should be used from about eight years of age if validated instruments are available.

Adverse reactions among children may differ qualitatively and quantitatively from those among adults because of developmental differences in pharmacokinetics, pharmacodynamics and organ maturity. Reactions that are well characterized for adults may present with different symptoms or at different thresholds for children, and entirely novel safety signals may emerge that were not anticipated from adult data. Adverse event grading tables have not been designed to specifically include neonatal adverse events, especially for preterm infants. The Neonatal Adverse Event Severity Scale was developed to address this gap, but more research is needed to harmonize adverse event reporting in this population.

Children are also at particular risk of long-term and delayed adverse effects such as effects on growth, pubertal development, fertility, bone density, cardiac function and cognitive development, which may manifest years after treatment, making long-term follow-up plans especially important.

Classifying and grading adverse events

The following systems may be used for classifying and grading adverse events for children included in clinical trials.

  1. The Medical Dictionary for Regulatory Activities is the internationally accepted standard for classifying adverse events for regulatory submissions. When using the Medical Dictionary for Regulatory Activities in paediatric trials, investigators should be aware that not all standard Medical Dictionary for Regulatory Activities queries are fully appropriate for children – age-group-specific presentations of a given safety concern may require the use of paediatric-appropriate preferred terms that capture the clinical presentation for children rather than adults.
  2. NCI Common Terminology Criteria for Adverse Events is a grading system most widely used in oncology trials that provides standardized severity grades (1–5) for a comprehensive range of adverse events. A Paediatric Patient-Reported Outcome version has been developed to enable children and adolescents to self-report symptomatic adverse events in age-appropriate language.
  3. The Neonatal Adverse Event Severity Scale  is designed to standardize the assessment and reporting of adverse-event severity for neonates, using criteria specifically relevant to newborns rather than adult-based scales. It provides generic and event-specific severity grading for 35 common neonatal adverse events, with the aim of improving consistency and interrater reliability across clinical trials, clinical care, safety surveillance and regulatory decision-making.

For non-oncology trials, investigators should discuss with the sponsor and statistical team which grading system is most appropriate and should ensure that the protocol and data management plan clearly define all grading conventions.

Reporting timelines and responsibilities

Key timelines under ICH E2A and applicable regulatory frameworks (ICH E6(R3), EU Clinical Trials Regulation 536/2014, United States Food and Drug Administration 21 CFR 312.32) are as follows: investigators must report all serious adverse events to the sponsor immediately – in most jurisdictions within 24 hours of becoming aware of the event. Sponsors must expedite reporting of suspected unexpected serious adverse reactions to all relevant regulatory authorities and ethics committees: fatal or life-threatening suspected unexpected serious adverse reactions within seven calendar days of the sponsor’s first knowledge and all other suspected unexpected serious adverse reactions within 15 calendar days. For paediatric trials, it is strongly recommended that the sponsor designates a paediatric pharmacovigilance expert to oversee causality assessment and clinical interpretation of adverse events, given the age-specific complexities described above.

The data safety monitoring board

An independent data safety monitoring board is recommended for most paediatric clinical trials and is required for all trials that involve significant risk, long treatment periods or vulnerable age groups such as neonates and infants. The data safety monitoring board provides independent oversight of accumulating safety data and has the authority to recommend trial modification or early termination if safety concerns emerge. Critically, the data safety monitoring board must include members with specific paediatric clinical expertise relevant to the condition under study and the age groups enrolled. The data safety monitoring board charter should specify stopping rules for both safety and efficacy or futility and should include prespecified criteria for reviewing adverse events by age group, since the safety profile may differ substantially between, for example, infants and adolescents enrolled in the same study. The frequency of data safety monitoring board meetings should be appropriate to the level of risk and the pace of enrolment; for early-phase studies among very young children or neonates, more frequent review may be warranted.

Active surveillance and eliciting adverse events among children

Passive adverse event reporting, in which events are only recorded when spontaneously reported by participants or caregivers, is insufficient for paediatric trials. Actively eliciting adverse events should be structured into all scheduled study visits through direct questioning of the child (using age-appropriate language) and the caregiver, supplemented by clinical assessment and laboratory monitoring. Symptom checklists adapted for the age group and the known or anticipated safety profile of the investigational product are recommended over open-ended enquiry alone, since systematic prompting substantially improves detection rates. Particular attention should be paid to adverse events that may be difficult to elicit among non-verbal children, including pain, nausea, changes in behaviour, sleep disturbance and changes in developmental milestones.

Developmental safety monitoring

In addition to standard adverse event monitoring, paediatric trials of any meaningful duration should incorporate structured monitoring of growth and development throughout the trial period. The protocol should specify scheduled assessments of height, weight, pubertal staging (Tanner scale) and developmental milestones appropriate to the age group. Longer-term follow-up studies may additionally assess bone density, cardiac function, neurocognitive development and reproductive health. The European Commission’s Ethical Considerations for Clinical Trials on Medicinal Products Conducted with Minors (2017) explicitly requires that the protocol justify the duration of follow-up and include assessment of child development whenre appropriate. If a drug is known or suspected to affect any developmental domain, specializsed assessments should be incorporated from the outset rather than added post hoc.

Communicating safety information to families

Families have a right to be informed about safety findings that may affect their decision to continue participating in the trial. When new safety information emerges, whether from the trial itself or from other sources, investigators should communicate this to families promptly and in plain language and should re-obtain consent or assent where required. The protocol should specify in advance how and when families will be informed of new safety findings, and the ethics committee should review this process as part of the initial protocol approval.

Key resources

Background resources